{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:37:32Z","timestamp":1795117052216,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1078"],"award-info":[{"award-number":["1078"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair deficiency setting, while safety and efficacy of combining dual-checkpoint inhibitor immunotherapy with chemotherapy remains uncertain. Here, we present results from the CCTG PA.7 study (NCT02879318), a randomized phase II trial comparing gemcitabine and nab-paclitaxel with and without immune checkpoint inhibitors durvalumab and tremelimumab in 180 patients with mPDAC. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and objective response rate. Results of the trial were negative as combination immunotherapy did not improve survival among the unselected patient population (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.72) and toxicity was limited to elevation of lymphocytes in the combination immunotherapy group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). Exploratory baseline circulating tumor DNA (ctDNA) sequencing revealed increased survival for patients with\n                    <jats:italic>KRAS<\/jats:italic>\n                    wildtype tumors in both the combination immunotherapy (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) and chemotherapy (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) groups. These data support the utility of ctDNA analysis in PDAC and the prognostic value of ctDNA-based\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutation status.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-32591-8","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T06:03:17Z","timestamp":1661493797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6089","authenticated-orcid":false,"given":"Daniel J.","family":"Renouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-2132","authenticated-orcid":false,"given":"Jonathan M.","family":"Loree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Topham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lemay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Tehfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Aucoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Joung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-3505","authenticated-orcid":false,"given":"Ravi","family":"Ramjeesingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-2583","authenticated-orcid":false,"given":"Christina A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-3617","authenticated-orcid":false,"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"32591_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. Ca. Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"Ca. Cancer J. Clin."},{"key":"32591_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"32591_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"32591_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"32591_CR5","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg, Z. A. et al. Open-label, Phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 26, 4814\u20134822 (2020).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"32591_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"32591_CR7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","volume":"10","author":"L Monteran","year":"2019","unstructured":"Monteran, L. & Erez, N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front. Immunol. 10, 1835 (2019).","journal-title":"Front. Immunol."},{"key":"32591_CR8","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","volume":"80","author":"K Ford","year":"2020","unstructured":"Ford, K. et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 80, 1846\u20131860 (2020).","journal-title":"Cancer Res."},{"key":"32591_CR9","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/bjc.2013.415","volume":"109","author":"R Alvarez","year":"2013","unstructured":"Alvarez, R. et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926\u2013933 (2013).","journal-title":"Br. J. Cancer"},{"key":"32591_CR10","first-page":"337","volume":"38","author":"T Miyashita","year":"2018","unstructured":"Miyashita, T. et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma. Anticancer Res. 38, 337\u2013343 (2018).","journal-title":"Anticancer Res."},{"key":"32591_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia, S. et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17, 299\u2013308 (2016).","journal-title":"Lancet Oncol."},{"key":"32591_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-20-1042","volume":"27","author":"ES Tsang","year":"2021","unstructured":"Tsang, E. S. et al. Delving into early-onset pancreatic ductal adenocarcinoma: how does age fit in? Clin. Cancer Res. J. Am. Assoc. Cancer Res. 27, 246\u2013254 (2021).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"32591_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"32591_CR14","doi-asserted-by":"publisher","unstructured":"Philip, P. A. et al. Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. clincanres.3581.2021 (2022) https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3581.","DOI":"10.1158\/1078-0432.CCR-21-3581"},{"key":"32591_CR15","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","volume":"25","author":"MR Jones","year":"2019","unstructured":"Jones, M. R. et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 25, 4674\u20134681 (2019).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"32591_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining, C. et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 8, 1087\u20131095 (2018).","journal-title":"Cancer Discov."},{"key":"32591_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","volume":"39","author":"C Luchini","year":"2020","unstructured":"Luchini, C. et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J. Exp. Clin. Cancer Res. CR 39, 227 (2020).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"32591_CR18","doi-asserted-by":"publisher","first-page":"E3861","DOI":"10.3390\/jcm9123861","volume":"9","author":"G Herbreteau","year":"2020","unstructured":"Herbreteau, G. et al. Circulating tumor DNA as a prognostic determinant in small cell lung cancer patients receiving Atezolizumab. J. Clin. Med. 9, E3861 (2020).","journal-title":"J. Clin. Med."},{"key":"32591_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","volume":"7","author":"JM Conroy","year":"2019","unstructured":"Conroy, J. M. et al. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J. Immunother. Cancer 7, 18 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"32591_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/1078-0432.CCR-20-1163","volume":"27","author":"A Pender","year":"2021","unstructured":"Pender, A. et al. Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumors. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 27, 202\u2013212 (2021).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"32591_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","volume":"19","author":"T Tsujikawa","year":"2017","unstructured":"Tsujikawa, T. et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 19, 203\u2013217 (2017).","journal-title":"Cell Rep."},{"key":"32591_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/PPO.0000000000000288","volume":"23","author":"SK Dougan","year":"2017","unstructured":"Dougan, S. K. The pancreatic cancer microenvironment. Cancer J. Sudbury Mass 23, 321\u2013325 (2017).","journal-title":"Cancer J. Sudbury Mass"},{"key":"32591_CR23","doi-asserted-by":"publisher","first-page":"e18581","DOI":"10.1097\/MD.0000000000018581","volume":"99","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Med. (Baltim.) 99, e18581 (2020).","journal-title":"Med. (Baltim.)"},{"key":"32591_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","volume":"31","author":"J Laskin","year":"2020","unstructured":"Laskin, J. et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann. Oncol. J. Eur. Soc. Med. Oncol. 31, 1693\u20131703 (2020).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"32591_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo.2017.10.14","volume":"9","author":"AL Windon","year":"2018","unstructured":"Windon, A. L. et al. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J. Gastrointest. Oncol. 9, 1\u201310 (2018).","journal-title":"J. Gastrointest. Oncol."},{"key":"32591_CR26","doi-asserted-by":"publisher","first-page":"109781","DOI":"10.1016\/j.envres.2020.109781","volume":"190","author":"M Porta","year":"2020","unstructured":"Porta, M. et al. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma. Environ. Res. 190, 109781 (2020).","journal-title":"Environ. Res."},{"key":"32591_CR27","doi-asserted-by":"publisher","first-page":"e60870","DOI":"10.1371\/journal.pone.0060870","volume":"8","author":"PS Rachakonda","year":"2013","unstructured":"Rachakonda, P. S. et al. Somatic mutations in exocrine pancreatic tumors: association with patient survival. PloS One 8, e60870 (2013).","journal-title":"PloS One"},{"key":"32591_CR28","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1002\/cncr.33038","volume":"126","author":"CA McIntyre","year":"2020","unstructured":"McIntyre, C. A. et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer 126, 3939\u20133949 (2020).","journal-title":"Cancer"},{"key":"32591_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg, M. M. et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br. J. Cancer 122, 333\u2013339 (2020).","journal-title":"Br. J. Cancer"},{"key":"32591_CR30","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly, E. M. et al. Randomized, multicenter, phase ii trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 Mutation. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 38, 1378\u20131388 (2020).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"32591_CR31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1136\/gutjnl-2020-320730","volume":"70","author":"RC Grant","year":"2021","unstructured":"Grant, R. C. et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut 70, 1894\u20131903 (2021).","journal-title":"Gut"},{"key":"32591_CR32","doi-asserted-by":"publisher","first-page":"viii36","DOI":"10.1093\/annonc\/mdz385","volume":"30","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. & Hechtman, J. F. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann. Oncol. J. Eur. Soc. Med. Oncol. 30, viii36\u2013viii40 (2019).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"32591_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547\u2013555 (2016).","journal-title":"Nat. Biotechnol."},{"key":"32591_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"32591_CR35","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara, D. R. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24, 1441\u20131448 (2018).","journal-title":"Nat. Med."},{"key":"32591_CR36","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove, G. et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 23, 6487\u20136497 (2017).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32591-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32591-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32591-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T06:16:36Z","timestamp":1661494596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32591-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32591"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32591-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.D. and S.J. are employees of Predicine. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5020"}}